genes, we compared the expression profiles of different conditions to derive early and late hypoxia response genes. Early responsive genes were those differentially expressed in the 6 h hypoxic condition compared with the ambient condition with at least 2-fold difference and p<0.05 by student's t-test. Late responsive genes were those showing at least 2-fold difference between 24 h hypoxia and ambient conditions and also displaying same regulation direction between 6 h and 24 h of hypoxia treatments. Early and late responsive genes were combined as the hypoxia response signature for SCP2 or LM2. Overlapping genes from the SCP2 and LM2 hypoxia response signatures were identified as the common hypoxia response signature (45 genes corresponding to 70 probe sets). Figure S6 . GSEA evaluation of the enrichment of previously defined gene sets in the ranked list of hypoxia response genes in LM2 and SCP2. A, GSEA evaluation of the enrichment of previously defined gene sets in the ranked list of hypoxia response genes in LM2 and SCP2. NES, normalized enrichment score. NOM p-val, nominal p-value. FDR q-val, false discovery rate q-value. B-C, enrichment plot (B) and heatmap (C) of the previously defined HIF-1α target genes (9), the up-regulated subset of the lung metastasis signature (LMS) (10) , and the up-regulated subset of the bone metastasis signature (BMS) (11) in the ranked list of hypoxia response genes in LM2 and SCP2. D, quantitative RT-PCR analysis of the mRNA level of selected genes when SCP2 or LM2 cells were treated with hypoxia for 0, 24, 36 and 48 hours. mRNA level was normalized to the housekeeping gene UBC. Data represent average ± SD. Figure S7 . Expression analysis and functional validation of DUSP1 as a bone metastasis gene. A, northern blot analysis of DUSP1 expression in MDA-MB-231 derivatives with different bone metastasis abilities (11) . ATCC denotes the parental MDA-MB-231 cell line. Sublines were obtained from in vivo selection of MDA-MB-231 with colors coded for their previously reported metastatic ability to bone: red, strong; orange, intermediate; green, weak (11) . B, effective knockdown of DUSP1 in SCP2 was confirmed by northern blot. C, DUSP1 silencing caused a significant reduction of bone metastasis burden as measured by BLI. Data represent average ± SE. ***, P<0.001 with MannWhitney test. N=10. D, expression level of DUSP1 in primary breast tumors with or without subsequent development of bone metastasis (BM) or lung metastasis (LM). Expression levels of DUSP1 were extracted from the microarray data in a previous study (10) . Data represent average ± SE with p-value shown from two-sided Student's t-test. Figure S8 . Unsupervised hierarchical clustering of breast cancer patients (Minn et al. dataset) using the LM2 hypoxia response signature. Dotted blue line separates the two biggest branches in the dendrogram. Bone metastasis and lung metastasis incidences are shown below the heatmap by color coding: red for metastasis incidence, green for metastasis-free or metastasis at other sites, and gray for unspecified. Figure S9 . Unsupervised Hierarchical clustering of breast cancer patients (Minn et al. dataset) with SCP2 hypoxia response signature. Dotted blue line separates the two biggest branches in the dendrogram. Bone metastasis and lung metastasis incidences are shown below the heatmap by color coding: red for metastasis incidence, green for metastasis-free or metastasis at other sites, and gray for unspecified. Figure S10 . Primary tumor growth after mammary fat pad injection of mixtures of SCP2 and LM2 cells at various ratios. A, volume measurement of primary tumors formed by mixtures of SCP2 and LM2 at various ratios. Five mixtures were injected, with percentage of each cell line in each mixture indicated. B, proliferation of LM2, which was labeled with a Renilla luciferase (Rluc) reporter, in the mixed tumor mass was measured by Rluc BLI. Note only four mixtures were measured as the mixture with no LM2 showed only background Rluc reading. The BLI signals were normalized to the input percentage of LM2 and shown in the plot at the left. The absolute Rluc BLI readings is shown in the plot at the right. C, proliferation of SCP2, labeled with firefly luciferase (Fluc), in the mixed tumor mass was measured by Fluc BLI. Note only four mixtures were measured as the mixture containing no SCP2 showed only background Fluc reading. The BLI signals were normalized to the initial input Fluc signals of SCP2 (corresponding to its percentages) and shown in the plot at the left. The absolute Fluc BLI readings is shown in the plot at the right. D, representative mice of Rluc and Fluc BLI of week 3. Rluc and Fluc BLI were performed on two consecutive days to avoid residual signal cross-contamination. Note no Fluc signals were detected for mice with 0% SCP2 input at implantation (first mouse in the top low), and no Rluc signals were detected for mice with 0% LM2 input at implantation (last mouse in the bottom row). Supplementary Table S1 . Lung metastasis signature (10) 206556_at  RA337M  216488_s_at ATPIH  210507_s_at p92  207538_at  BSF1  220113_x_at RPA135  215842_s_at ATPIH  205539_at  p92  204591_at  CALL  218347_at  RSAFD1  213582_at  ATPIH  221123_x_at PBF  219834_at  CARF  203332_s_at SHIP  218595_s_at BAP28  218149_s_at PBF  203868_s_at CD106  203331_s_at SHIP  218594_at  BAP28  209687_at  PBSF  202351_at  CD51  219480_at  SNA  220977_x_at BE37  203666_at  PBSF  210606_x_at CD94  207102_at  SRD5B1  209373_at  BENE  207317_s_at PDIB2  207796_x_at CD94  219898_at  SREB  204422_s_at BFGF  202464_s_at PFK2  207795_s_at CD94  206312_at  STAR  204421_s_at BFGF  217383_at  PGKA  44783_s_at  CHF2  219915_s_at TAT1  206787_at  BRD6  217356_s_at PGKA  218839_at  CHF2  207893_at  TDF  220272_at  BSN2  200738_s_at PGKA  205476_at  CKb4  217567_at  TGP  219534_x_at BWS  200737_at  PGKA  214235_at  CP35  217566_s_at TGP  219533_at  BWS  202239_at  PH5P  214234_s_at CP35  206260_at  TGP  216894_x_at BWS  219232_s_at PHD3  205765_at  CP35  221060_s_at TOLL  213348_at  BWS  217705_at  PKD  207096_at  CSAA  215775_at  TSP  213183_s_at BWS  205880_at  PKD  211339_s_at EMT  201110_s_at TSP  213182_x_at BWS  219652_s_at PRO3743  206349_at  EPT  201109_s_at TSP  220088_at  C5A  204469_at  PTPZ  214589_at  FHF1  201108_s_at TSP  204865_at  Car3  210479_s_at ROR1  207501_s_at FHF1  201107_s_at TSP  209474_s_at CD39  210426_x_at ROR1  203854_at  FI  220578_at  TSRC1  209473_at  CD39  218711_s_at SDR  220256_s_at FKSG25  221477_s_at  207691_x_at CD39  215865_at  SRG1  220628_s_at FLJ10832  220893_at  203441_s_at CDHN  215860_at  SRG1  220361_at  FLJ12476  220614_s_at  203440_at  CDHN  203439_s_at STC-2  220346_at  FLJ13105  220324_at  220132_s_at CLAX  203438_at  STC-2  219353_at  FLJ20147  220156_at  FLJ11767  202936_s_at CMD1  209813_x_at TARP  216096_s_at FLJ35941  219277_s_at OGDHL  202935_s_at CMD1  210487_at  TDT  209915_s_at FLJ35941  218925_s_at FLJ23499  209047_at  CO  215685_s_at TES1  209914_s_at FLJ35941  218633_x_at FLJ11342  207542_s_at CO  207147_at  TES1  210750_s_at GKAP  216879_at  206515_at  CPF3  201860_s_at TPA  206490_at  GKAP  216872_at  210815_s_at CRLR  205047_s_at TS11  206489_s_at GKAP  215704_at  FLG  206331_at  CRLR  204951_at  TTF  207447_s_at GNTIVH  212906_at  213782_s_at CS-1  201131_s_at UVO  219508_at  GnT-M  212531_at  NGAL  211476_at  CS-1  201130_s_at UVO  204470_at  GRO1  209795_at  CLEC2C  207148_x_at CS-1  209822_s_at VLDLRCH  209774_x_at GRO2  208463_at  GABRA4  202887_s_at Dig2  222353_at  LIMD1  207850_at  GRO3  207826_s_at HEIR-1  202747_s_at E25A  221730_at  MGC105115 209618_at  GT24  207063_at  PRO2834  202746_at  E25A  221729_at  MGC105115 209617_s_at GT24  206824_at 221123_x_at PBF  216598_s_at HC11  217388_s_at KYNU  203865_s_at RED1  211434_s_at HCR  216257_at  207999_s_at RED1  205207_at  HGF  215817_at  209979_at  RED1  211604_x_at HLP  215704_at  FLG  206828_at  RLK  211222_s_at HLP  215436_at  201810_s_at SAB  204667_at  HNF3A  215309_at  201811_x_at SAB  216624_s_at HRX  214413_at  TAT  204541_at  SPF  212079_s_at HRX  214357_at  RP1-106H8.1  219915_s_at TAT1  212078_s_at HRX  214261_s_at ADH-5  206893_at  TBS  212076_at  HRX  212531_at  NGAL  205254_x_at TCF-1  220301_at  HsT1731  212080_at  LOC143941  205255_x_at TCF-1  217272_s_at HUR7  211601_at  221371_at  TL6 
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